

# Klemens Fheodoroff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5510342/publications.pdf>

Version: 2024-02-01

54  
papers

572  
citations

759233

12  
h-index

677142

22  
g-index

69  
all docs

69  
docs citations

69  
times ranked

492  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results from the Upper Limb International Spasticity Study-II (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. <i>BMJ Open</i> , 2013, 3, e002771.	1.9	64
2	An international survey of patients living with spasticity. <i>Disability and Rehabilitation</i> , 2017, 39, 1428-1434.	1.8	44
3	Diagnosis and treatment of neurogenic dysphagia – S1 guideline of the German Society of Neurology. <i>Neurological Research and Practice</i> , 2021, 3, 23.	2.0	38
4	Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. <i>BMJ Open</i> , 2013, 3, e002230.	1.9	37
5	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. <i>Journal of Neural Transmission</i> , 2021, 128, 321-335.	2.8	37
6	Common goal areas in the treatment of upper limb spasticity: a multicentre analysis. <i>Clinical Rehabilitation</i> , 2016, 30, 617-622.	2.2	34
7	Effectiveness of Integration and Re-Integration into Work Strategies for Persons with Chronic Conditions: A Systematic Review of European Strategies. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 552.	2.6	28
8	Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III). <i>BMJ Open</i> , 2016, 6, e011157.	1.9	27
9	Consensus statement: Botulinum toxin in myofacial pain. <i>Journal of Neurology</i> , 2004, 251, i36-i38.	3.6	25
10	Mapping European Welfare Models: State of the Art of Strategies for Professional Integration and Reintegration of Persons with Chronic Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 781.	2.6	21
11	Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. <i>Frontiers in Neurology</i> , 2020, 11, 104.	2.4	19
12	Factors Influencing Goal Attainment in Patients with Post-Stroke Upper Limb Spasticity Following Treatment with Botulinum Toxin A in Real-Life Clinical Practice: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study. <i>Toxins</i> , 2015, 7, 1192-1205.	3.4	17
13	Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. <i>Journal of Rehabilitation Medicine</i> , 2021, 53, jrm00157.	1.1	17
14	A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children. <i>Disability and Rehabilitation</i> , 2020, , 1-11.	1.8	15
15	Experienced complaints, activity limitations and loss of motor capacities in patients with pure hereditary spastic paraplegia: a web-based survey in the Netherlands. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 64.	2.7	13
16	Spasticity or reversible muscle hypertonia?. <i>Journal of Rehabilitation Medicine</i> , 2011, 43, 556-557.	1.1	11
17	Policy Guidelines for Effective Inclusion and Reintegration of People with Chronic Diseases in the Workplace: National and European Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 493.	2.6	11
18	Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 51.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study. Journal of Rehabilitation Medicine, 2021, 53, jrm00133.	1.1	11
20	How Can We Improve Current Practice in Spastic Paresis?. European Neurological Review, 2016, 11, 79.	0.5	11
21	Furthering the Evidence of the Effectiveness of Employment Strategies for People with Mental Disorders in Europe: A Systematic Review. International Journal of Environmental Research and Public Health, 2018, 15, 838.	2.6	9
22	Time to retreatment with botulinum toxin A in upper limb spasticity management: Upper limb international spasticity (ULIS)-III study interim analysis. Toxicon, 2018, 156, S110-S111.	1.6	7
23	Ixcellence Network <sup>1/2</sup> : an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. Functional Neurology, 2017, 32, 103.	1.3	7
24	ULIS (Upper Limb International Spasticity), a 10-year Odyssey. The Journal of the International Society of Physical and Rehabilitation Medicine, 2019, 2, 138-150.	0.3	6
25	Phenotype and Ctg-Repeat Size in Myotonic Dystrophy: A Study of 26 Patients and 55 Relatives. Journal of Neurogenetics, 1999, 13, 181-190.	1.4	5
26	Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses. Clinical Therapeutics, 2019, 41, 2321-2330.e4.	2.5	5
27	Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study. Disability and Rehabilitation, 2020, , 1-7.	1.8	5
28	Validity and Reliability of the Spasticity-Associated Arm Pain Scale. Journal of Pain Management & Medicine, 2017, 03, .	0.2	5
29	Identifying the Employment Needs of People With Chronic Health Conditions in Europe. Journal of Occupational and Environmental Medicine, 2018, 60, e618-e624.	1.7	4
30	Spastic Paresis and Rehabilitation – The Patient Journey. European Neurological Review, 2016, 11, 87.	0.5	4
31	Integrated upper limb spasticity management including botulinum toxin A (BoNT-A) on patient-centred goal attainment: Methodology for ULIS-III and initial goal-setting data. Toxicon, 2016, 123, S81.	1.6	2
32	Do randomised controlled trials evaluating functional outcomes following botulinum neurotoxin-A align with focal spasticity guidelines? A systematic review. Disability and Rehabilitation, 2022, 44, 8515-8523.	1.8	2
33	Efficacy of Four-Channel Functional Electrical Stimulation on Moderate Arm Paresis in Subacute Stroke Patients – Results from a Randomized Controlled Trial. Healthcare (Switzerland), 2022, 10, 704.	2.0	2
34	Economic outcomes in real-world use of botulinum toxin-A products for adult patients with upper limb spasticity: A UK perspective. Toxicon, 2021, 190, S73.	1.6	1
35	Real-life data on the time to retreatment with botulinum toxin type A in upper limb spasticity management. Toxicon, 2021, 190, S34.	1.6	1
36	The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: Development and responsiveness. Journal of Rehabilitation Medicine, 2021, , .	1.1	1

#	ARTICLE	IF	CITATIONS
37	The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: A first psychometric evaluation. Journal of Rehabilitation Medicine, 2021, , .	1.1	1
38	Outcomes Related to Passive Function in a Cohort of Patients Treated With Botulinum Toxin A (Bont-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study. PM and R, 2013, 5, S235-S235.	1.6	0
39	Outcomes Related to Pain in a Cohort of Patients Treated with Botulinum Toxin A (BoNT-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study. PM and R, 2013, 5, S243-S243.	1.6	0
40	Outcomes Related to Active Function in a Cohort of Patients Treated With Botulinum Toxin A (Bont-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study. PM and R, 2013, 5, S240-S240.	1.6	0
41	Upper Limb International Spasticity Study-II (ULIS-II): Results of a Large, International, Prospective Cohort Study Investigating Practice and Goal Attainment Following Treatment With Botulinum Toxin A in Real-Life Clinical Management. PM and R, 2013, 5, S238-S239.	1.6	0
42	110. Factors influencing goal attainment in patients with poststroke upper limb spasticity following treatment with botulinum neurotoxin A in real-life clinical practice: subanalyses from the Upper Limb International Spasticity (ULIS)-II Study. Toxicon, 2015, 93, S33-S34.	1.6	0
43	Correlations between spasticity, goal attainment, and global assessment of benefits in patients with upper limb spasticity treated with botulinum toxin A. Toxicon, 2016, 123, S20-S21.	1.6	0
44	An innovative international educational network to improve physicians' current management practices for patients with cervical dystonia and spasticity. Toxicon, 2016, 123, S41.	1.6	0
45	A comparison of goal selection and achievement between botulinum toxin A (BoNT-A) naïve and non-naïve patients in the upper limb international spasticity (ULIS)-II study. Toxicon, 2016, 123, S59-S60.	1.6	0
46	Poster 373â€ Integrated Upper Limb Spasticity Management Including Botulinum Toxin A (BoNTâ€A) on Patientâ€Centered Goal Attainment: Methodology for ULISâ€II and Initial Goalâ€Setting Data. PM and R, 2016, 8, S331.	1.6	0
47	Poster 313 Relationship Between AbobotulinumtoxinA Injections into Shoulder Muscles and Patient Centred Primary Goal Selection and Achievement: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study. PM and R, 2016, 8, S262.	1.6	0
48	Poster 57: Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management: Initial Data from the Upper Limb International Spasticity (ULIS)â€III Study. PM and R, 2017, 9, S155.	1.6	0
49	Poster 52: Botulinum Toxin A in Upper Limb Spasticity Management: Baseline Data from the Upper Limb International Spasticity (ULIS)-III Study. PM and R, 2018, 10, S25-S25.	1.6	0
50	Poster 55: Relief of Spasticity-Related Pain with Botulinum Neurotoxin-A (BoNT-A) in Real Life Practice. Post-Hoc Analysis from a Large International Cohort Series. PM and R, 2018, 10, S25-S26.	1.6	0
51	The spasticity-related quality of life 6-dimensions tool (SQoL-6D) in upper limb spasticity: A first psychometric evaluation. Toxicon, 2021, 190, S73-S74.	1.6	0
52	Clinical Trial Adherence to Focal Muscle Spasticity Guidelines: A Systematic Review. Archives of Physical Medicine and Rehabilitation, 2021, 102, e112.	0.9	0
53	ICF basierte Zielsetzung in der Funktionellen Elektrostimulation. , 2021, , 49-58.		0
54	Kombinationstherapien mit der Funktionellen Elektrostimulation. , 2021, , 181-199.		0